Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Role of Fexofenadine in Reducing Albuminurea in Patients With Diabetic Kidney Disease

NCT04224428 is registered in ClinicalTrials.gov with Tanta University as lead sponsor.

NCT NCT04224428
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04224428 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Role of Fexofenadine in Reducing Albuminurea in Patients With Diabetic Kidney Disease
Lead sponsor
Tanta University
Phase
Phase 3
Overall status
Completed
Start date
January 1, 2020
Completion date
February 1, 2022
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic kidney disease